Mydecine Innovations Group 과거 수익 실적

과거 기준 확인 0/6

Mydecine Innovations Group은 연평균 8.7%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 12.9%의 비율로 수입이 증가했습니다. 매출은 연평균 73.5%의 비율로 감소했습니다.

주요 정보

8.7%

수익 성장률

68.4%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	-73.5%
자기자본 수익률	n/a
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Mydecine Innovations Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:0NF0 수익, 비용 및 수입 (CAD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-12	4	3
30 Jun 24	-12	4	2
31 Mar 24	-11	5	1
31 Dec 23	-21	8	1
30 Sep 23	-19	11	2
30 Jun 23	-20	12	2
31 Mar 23	-21	13	3
31 Dec 22	-16	12	4
30 Sep 22	-23	15	4
30 Jun 22	-18	16	4
31 Mar 22	-24	17	5
31 Dec 21	-24	18	4
30 Sep 21	-19	12	3
30 Jun 21	-37	14	3
31 Mar 21	-32	14	2
31 Dec 20	-27	10	1
30 Sep 20	-39	9	0
30 Jun 20	-23	5	0
31 Mar 20	-20	2	0
31 Dec 19	-21	3	0
30 Sep 19	-5	5	0
30 Jun 19	-5	5	0
31 Mar 19	-11	6	0
31 Dec 18	-13	6	0
30 Sep 18	-22	12	0
30 Jun 18	-21	11	0
31 Mar 18	-18	13	0
31 Dec 17	-18	15	0
30 Sep 17	-14	10	0
30 Jun 17	-14	10	0
31 Mar 17	-11	7	0
31 Dec 16	-8	4	0
30 Sep 16	-1	1	0
30 Jun 16	-1	1	0
31 Mar 16	-3	3	0
31 Dec 15	-4	4	0
30 Sep 15	-4	4	0
30 Jun 15	-4	4	0
31 Mar 15	-2	1	0
31 Dec 14	-1	1	0
30 Sep 14	-1	0	0
31 Mar 14	0	0	0
31 Dec 13	0	0	0

양질의 수익: 0NF0 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 0NF0 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 0NF0 은(는) 수익성이 없지만 지난 5년 동안 연간 8.7% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 0NF0 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 0NF0 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 28.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 0NF0 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Mydecine Innovations Group 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

Full year 2021 earnings released

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

First half earnings released

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

First half earnings released

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

New 90-day low - €0.24

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석